Biomimetic Cardiac Fibrotic Model for Antifibrotic Drug Screening
Tissue Engineering Part C: Methods · 01.12.2023 · 29 (12) · 558-571
DOI: 10.1089/ten.tec.2023.0089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tissue Engineering Part C: Methods, online erschienen am 11.12.2023. Verfasst von Haiyan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Scie…. Hauptthemen laut MEDLINE: Biomimetics, Fibroblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Cardiac fibrosis is characterized by pathological proliferation and activation of cardiac fibroblasts to myofibroblasts. Inhibition and reverse of transdifferentiation of cardiac fibroblasts to myofibroblasts is a potential strategy for cardiac fibrosis. Despite substantial progress, more effort is needed to discover effective drugs to improve and reverse cardiac fibrosis. The main reason for the slow development of antifibrotic drugs is that the traditional polystyrene culture platform does not recapitulate the microenvironment where cells reside in tissues. In this study, we propose an in vitro cardiac fibrotic model by seeding electrospun yarn scaffolds with cardiac fibroblasts. Our results show that yarn scaffolds allow three-dimensional growth of cardiac fibroblasts, promote extracellular matrix (ECM) deposition, and induce the transdifferentiation of cardiac fibroblasts to myofibroblasts. Exogenous transforming growth factor-β1 further promotes cardiac fibroblast activation and ECM deposition, which makes it a suitable fibrotic model to predict the antifibrotic potential of drugs. By using this platform, we demonstrate that both Honokiol (HKL) and Pirfenidone (PFD) show potential in antifibrosis to some extent. HKL is more efficient in antifibrosis than PFD as revealed by biochemical composition, gene, and molecular analyses as well as histological and biomechanical analysis. The electrospun yarn scaffold provides a novel platform for constructing in vitro fibrotic models to study cardiac fibrosis and to predict the antifibrotic efficacy of novel drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai, P.R. China.
- Department of Pediatric Cardiothoracic Surgery, Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease, Shanghai Children's Medical Center, National Children's Medical Center, School of Medicine, Shan…
ORCID-Profile: Jinglei Wu
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Li, H., Zhu, Y., Chen, Z., Ma, Q., Abd-Elhamid, A. I., Feng, B., Sun, B., & Wu, J. (2023). Biomimetic Cardiac Fibrotic Model for Antifibrotic Drug Screening. Tissue Engineering Part C: Methods, 29(12), 558-571. https://doi.org/10.1089/ten.tec.2023.0089
Vancouver
Li H, Zhu Y, Chen Z, Ma Q, Abd-Elhamid AI, Feng B, et al. Biomimetic Cardiac Fibrotic Model for Antifibrotic Drug Screening. Tissue Engineering Part C: Methods. 2023;29(12):558-571. doi:10.1089/ten.tec.2023.0089
BibTeX
@article{Li2023,
author = {Li, Haiyan and Zhu, Yifan and Chen, Zhe and Ma, Qiaolin and Abd-Elhamid, Ahmed I and Feng, Bei and Sun, Binbin and Wu, Jinglei},
title = {Biomimetic Cardiac Fibrotic Model for Antifibrotic Drug Screening},
journal = {Tissue Engineering Part C: Methods},
year = {2023},
volume = {29},
number = {12},
pages = {558--571},
doi = {10.1089/ten.tec.2023.0089}
}
EUVIMED